Revive Therapeutics Clarifies Completion of Key Nerve Agent Countermeasure Study
TORONTO, July 08, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or…
AJA Health and Wellness Inc. Provides Update on Delay in Filing Financial Statements
July 08, 2025 16:48 ET | Source: Aja Health and Wellness Inc.…
UAE Approves BioAros Longevity+ Supplement, Signaling Major Market Potential in Global Preventive Health
CALGARY, Alberta, July 08, 2025 (GLOBE NEWSWIRE) -- In a significant move…
AB Science announces the successful completion of a EUR 1.925 million private placement
PRESS RELEASE AB SCIENCE ANNOUNCES THE SUCCESSFUL COMPLETION OF A EUR 1.925…
Basilea receives USD 39 million funding under BARDA agreement to continue to advance novel antifungals fosmanogepix and BAL2062
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, July 08,…
Diginex Announces Plans for Eight-for-One Forward Stock Split
July 07, 2025 23:29 ET | Source: Diginex Limited LONDON, July 07,…
NIOs firefly brand taps HERE Technologies to power smart, connected EV journeys
firefly will use HERE’s high-quality map data in global markets to enhance…
Ripple’s national license is imminent, and RICH Miner helps XRP investors create higher real value
New York City, NY, July 07, 2025 (GLOBE NEWSWIRE) -- Ripple (XRP)…
UroGen Announces Completion of Enrollment in the Phase 3 UTOPIA Clinical Trial of UGN-103 for the Treatment of Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
PRINCETON, N.J., July 07, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq:…
LENZ Therapeutics and Laboratoires Tha Announce Exclusive License and Commercialization Agreement for LNZ100 in Canada
Exclusive agreement includes over $70 million in upfront and milestone payments to…
